DE3130606A1 - Agent for forming antibodies - Google Patents

Agent for forming antibodies

Info

Publication number
DE3130606A1
DE3130606A1 DE19813130606 DE3130606A DE3130606A1 DE 3130606 A1 DE3130606 A1 DE 3130606A1 DE 19813130606 DE19813130606 DE 19813130606 DE 3130606 A DE3130606 A DE 3130606A DE 3130606 A1 DE3130606 A1 DE 3130606A1
Authority
DE
Germany
Prior art keywords
particles
recipient organism
antibody formation
organism
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19813130606
Other languages
German (de)
Other versions
DE3130606C2 (en
Inventor
Rolf Dr. 8700 Würzburg Siegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19813130606 priority Critical patent/DE3130606C2/en
Publication of DE3130606A1 publication Critical patent/DE3130606A1/en
Application granted granted Critical
Publication of DE3130606C2 publication Critical patent/DE3130606C2/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum

Abstract

Published without abstract.

Description

Mittel zur Nntikörperbildung, Means for producing antibodies,

Die Erfindung betrifft o. g. Mittel und findet vor allem dort anwendung, wo große Engen Antikörper benötigt werden, beispielsweise als Therapeutika oder für analytische Zwecke (Radioimmunassays), bzw.The invention relates to the above. Means and is mainly used there, where large narrow antibodies are needed, for example as therapeutics or for analytical purposes (radioimmunoassays), resp.

als Liganden bei der Affinitätschromatographie.as ligands in affinity chromatography.

Die herkömmliche Methode der artifiziell induzierten Antikörperbildung beruht im wesentlichen auf der Applikation eines, in einem AdJuvans gelösten Antigens in einen geeigneten Empfängerorganismus. Das bekannteste Adjuvans dieser Art ist das Freund'sche adjuvans, einer Suspension aus Wineralöl,Detergenz und abgetöteten Tuberkelbazillen. Der Empfängerorganismus bildet, wahrscheinlich wegen der verringerten Absorptionsgeschwindigkeit hochtoxischer Antigene und deren verlängerten tiontaktzeit an den Rezeptoren der Lymphozatenoberflchen, vergleichsweise größere und über langere Zeit anhaltende Antikörpermengen.The traditional method of artificially induced antibody generation is essentially based on the application of an antigen dissolved in an AdJuvan into a suitable recipient organism. The best known adjuvant of this type is the Freund's adjuvant, a suspension of mineral oil, detergent and killed Tubercle bacilli. The recipient organism forms, probably because of the decreased Absorption speed of highly toxic antigens and their extended cycle time at the receptors of the lymphocyte surface, comparatively larger and longer Sustained amounts of antibody over time.

Die Reinigung der im Empfängerorganismus gebildeten und im Blutplasma vorliegenden Antikörper erfolgt üblicherweise durch Präzipitationstechniken (Cohn' sehe raktionierung) oder durch Ohromatoraphietechniken. Vor allem die Affinitätschromatographie ist in vielen Fällen mittel der Wahl, da selektiv gegen das applizierte Antigen gerichtete Antikörper erhalten werden.The purification of those formed in the recipient organism and in the blood plasma present antibodies are usually carried out by precipitation techniques (Cohn ' see ractioning) or through earmatoraphy techniques. Especially affinity chromatography is in many cases the means of choice because it is selective against the applied antigen directed antibodies can be obtained.

Histologisch findet sich am Applikationsort des.Antigens eine ausgeprägte Zellinfiltration, u.a. mit Plasmazellerl, Lymphozyten und lionozyten. Diese Zeilen sind an der Antikörperbildung beteiligt und sind Gegenstand intensiver Untersuchungen, vor allem im Hinblick auf eine Antikörperproduktion in vitro. -Da das Antigen in gelöster k'orm dem Empfängerorganismus appliziert wird, ist es bisher nicht möglich, es zusammen mit an der Antikörperbildung beteiligten Zellen zu isolieren.Histologically, there is a pronounced at the application site of the antigen Cell infiltration, including with plasma cells, lymphocytes and lionocytes. These lines are involved in antibody formation and are the subject of intensive investigations, especially in With regard to antibody production in vitro. -There the antigen is applied to the recipient organism in dissolved form, it has been so far it is not possible to isolate it together with cells involved in antibody formation.

Der Erfindung liegt die Aufgabe zugrunde, ein Mittel zu finden, das es ermöglicht, a)-eine langanhaltende, hochspezifische Antikörperbildung in einem dazu -befähigten Organismus zu erzielen, b) eine hochspezifische Reinigung der gebildeten Antikörper aus dem Blutplasma des Empfängerorganismus zu erreichen, c) seine gemeinsame Isolierung zusammen mit Zellen, die an der Antikörperbildung beteiligt sind, aus dem Empfängerorganismus in vivo jederzeit durchzuführen.The invention is based on the object of finding a means that it enables a) -a long-lasting, highly specific antibody formation in one to achieve this-capable organism, b) a highly specific purification of the formed To reach antibodies from the blood plasma of the recipient organism, c) its common Isolation together with cells that are involved in antibody formation the recipient organism in vivo at any time.

Erfindungsgemäß wird die Aufgabe dadurch gelost, daß es sich bei dem gesuchten mittel um mit Antigen beladene Partikel aus einem immunbiologisch inerten Material handelt, die a) einem zur Antikörperbildung befähigten Organismus in geeigneter Weise zugeführt werden, die b) zur affinitätschromatographischen Reinigung der gebildeten Antikörper aus dem Blutplasma verwendet werden und die c) in Form einer Suspension in natürliche und/ oder künstlich geschaffene Körperhöhlen des Empfängerorganismus appliziert werden, woraus sie zusammen mit an der Antikörpertildung beteiligten Zellen des Empfängerorganismus, vorzugsweise durch Punktion, wieder entfernt werden.According to the invention the object is achieved in that it is the sought agent for antigen-laden particles from an immunobiologically inert Material is that a) an organism capable of producing antibodies in a suitable Way are supplied, the b) for affinity chromatographic purification of the formed Antibodies from the blood plasma can be used and the c) in the form of a suspension in natural and / or artificially created body cavities of the recipient organism are applied, from which they together with involved in the formation of antibodies Cells of the recipient organism are removed again, preferably by puncture.

Die Beladung der immunbiologisch inerten Partikel erfolgt u.a. durch an sich bekan-nte "solid phase"-Techniken: durch mittelbare. -ant*t Verwendung eines "spacers " - undioder unmittelbare adsorptive und/oder kovalente Bindung des Antigens an die immunbiologisch inerten Partikel (siehe hierzu: Mosbach, Klaus (Hrsg.): Methods in rnzymology, Volume OLIV: Academic Press, New Kork, San Francisco, London (1976)).The loading of the immunobiologically inert particles is carried out, among other things, by "solid phase" techniques known per se: through indirect. -ant * t use a "spacers "- and / or direct adsorptive and / or covalent Binding of the antigen to the immunologically inert particles (see: Mosbach, Klaus (Ed.): Methods in Enzymology, Volume OLIV: Academic Press, New Kork, San Francisco, London (1976)).

Als im!nunbiologisch inerte Partikel eignen sich u.a.As im! Nunbiologically inert particles are i.a.

Kunststoff- und/oder Glas--und/oder Keramik- und/oder Metallpartikel, die in einer Vielfalt von Ausbildungen, wie z.B. unterschiedliche Formen, Oberflächen, Texturen, Dimensionierungen, Porengrößen etc. erhältlich sind.Plastic and / or glass and / or ceramic and / or metal particles, which come in a variety of forms, such as different shapes, surfaces, Textures, dimensions, pore sizes etc. are available.

Bewährt haben sich vernetzte Polystyrolpartikel, wie sie üblicherweise zur Gelpermeationschromatographie verwendet werdenCrosslinked polystyrene particles, as they are usually used, have proven useful be used for gel permeation chromatography

Claims (4)

Patentansprüche 1. Mittel zur Antikörperbildung, zur selektiven Antikörperreinigung sowie zur Isolierung von an der Antikörperbildung beteiligter Zellen, dadurch gekennzeichnet, da es sich hierbei jeweils um mit Antigen beladene:Partikel aus einem imrnunbiologisch inerten Material handelt, die einem zur Antikörperbildung befähigten Organismus in geeigneter Weise zugeführt werden, die zur affinitätschromatographischen Reinigung der im Blutplasma vorliegenden vom Empfängerorganismus gebildeten Antikörper verwendet werden und die in Form einer Suspension in natürliche und/oder künstlich geschaffene Körperhöhlen des Empfängerorganismus appliziert werden, woraus sie jederzeit in vivo zusammen mit den an der Antikörperbildung beteiligten Zellen des Empfängerorganismus, vorzugsweise durch Punktion, wieder entfernt werden.Claims 1. Means for antibody formation, for selective antibody purification and for the isolation of cells involved in antibody formation, characterized in that since these are each loaded with antigen: particles from an immunobiological is inert material, which is an organism capable of producing antibodies are supplied in a suitable manner for affinity chromatographic purification the antibodies formed by the recipient organism in the blood plasma are used and those in the form of a suspension in natural and / or artificially created Body cavities of the recipient organism are applied, from which they are at any time in vivo together with the cells of the recipient organism that are involved in antibody formation, preferably by puncture. 2. Ritzel nach Anspruch 1, dadurch gekennzeichnet, daß die Partikel durch Adsorption und/oder kovalente Bindung mittel- und/oder unmittelbar mit einem oder mehreren Antigenen u.a. durch an sich bekannte solid phase!' Techniken beladen werden.2. Pinion according to claim 1, characterized in that the particles by adsorption and / or covalent bonding indirectly and / or directly with a or several antigens, inter alia, through a solid phase known per se! ' Loading techniques will. 3. Mittel nach Anspruch 1, dadurch gekennzeichnet, daß es sich bei den immunbiologisch inerten Partikeln u.a.3. Means according to claim 1, characterized in that it is at the immunobiologically inert particles, etc. um Kunststoff- und/oder Glas- und/oder Keramik- und/ oder Metallpartikel handelt9 die dem Verwendungszweck optimal angepasst sind.around plastic and / or glass and / or ceramic and / or metal particles acts9 which are optimally adapted to the intended use. 4. Mittel nach Anspruch 3, dadurch gekennzeichnet, daß es sich dabei um üblicherweise für chromatographische Zwecke verwendete vernetzte Polystyrolpartikel handelt.4. Means according to claim 3, characterized in that it is to cross-linked polystyrene particles commonly used for chromatographic purposes acts.
DE19813130606 1981-08-01 1981-08-01 Method for the isolation of cells involved in antibody formation Expired DE3130606C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19813130606 DE3130606C2 (en) 1981-08-01 1981-08-01 Method for the isolation of cells involved in antibody formation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813130606 DE3130606C2 (en) 1981-08-01 1981-08-01 Method for the isolation of cells involved in antibody formation

Publications (2)

Publication Number Publication Date
DE3130606A1 true DE3130606A1 (en) 1983-02-17
DE3130606C2 DE3130606C2 (en) 1985-03-21

Family

ID=6138424

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19813130606 Expired DE3130606C2 (en) 1981-08-01 1981-08-01 Method for the isolation of cells involved in antibody formation

Country Status (1)

Country Link
DE (1) DE3130606C2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046723A (en) * 1976-04-22 1977-09-06 The Dow Chemical Company Azide bonding of a protein to a latex
DE2740008A1 (en) * 1976-09-27 1978-03-30 Corning Glass Works PROCESS FOR THE IMMOBILIZATION OF BIOLOGICALLY ACTIVE PROTEINS
DE2615349B2 (en) * 1975-04-09 1978-06-15 Snamprogetti S.P.A., Mailand (Italien) Method for immobilizing antigens, enzymes and enzyme inhibitors
DE2905657A1 (en) * 1978-02-14 1979-08-16 Sanyo Chemical Ind Ltd CONJUGATES OF IMMUNOLOGICALLY ACTIVE SUBSTANCE AND GLASS, PROCESS FOR THEIR PRODUCTION AND USE OF THE SAME
US4210723A (en) * 1976-07-23 1980-07-01 The Dow Chemical Company Method of coupling a protein to an epoxylated latex
DE3005771A1 (en) * 1979-02-15 1980-08-21 Eni Ente Naz Idrocarb METHOD FOR PRODUCING MICROPOROUS BODIES INCLUDING ONE OR MORE ACTIVE AGENTS
DE2201518B2 (en) * 1972-01-13 1980-12-18 Hugo Prof. Seinfeld Carrier-bound protein and method for its production - US Pat

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2201518B2 (en) * 1972-01-13 1980-12-18 Hugo Prof. Seinfeld Carrier-bound protein and method for its production - US Pat
DE2615349B2 (en) * 1975-04-09 1978-06-15 Snamprogetti S.P.A., Mailand (Italien) Method for immobilizing antigens, enzymes and enzyme inhibitors
US4046723A (en) * 1976-04-22 1977-09-06 The Dow Chemical Company Azide bonding of a protein to a latex
US4210723A (en) * 1976-07-23 1980-07-01 The Dow Chemical Company Method of coupling a protein to an epoxylated latex
DE2740008A1 (en) * 1976-09-27 1978-03-30 Corning Glass Works PROCESS FOR THE IMMOBILIZATION OF BIOLOGICALLY ACTIVE PROTEINS
DE2905657A1 (en) * 1978-02-14 1979-08-16 Sanyo Chemical Ind Ltd CONJUGATES OF IMMUNOLOGICALLY ACTIVE SUBSTANCE AND GLASS, PROCESS FOR THEIR PRODUCTION AND USE OF THE SAME
DE3005771A1 (en) * 1979-02-15 1980-08-21 Eni Ente Naz Idrocarb METHOD FOR PRODUCING MICROPOROUS BODIES INCLUDING ONE OR MORE ACTIVE AGENTS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bier, O.G. u. andere: Experimentelle und klinische Immunologie, Berlin 1979, S. 79-80 *

Also Published As

Publication number Publication date
DE3130606C2 (en) 1985-03-21

Similar Documents

Publication Publication Date Title
EP0134307B1 (en) Preactivated surfaces of synthetic materials for immobilizing organochemical and biological substances, process for preparing them and their use
DE2612948C2 (en) Reusable immobilized immunoadsorbent for a method of quantitative analysis of the antigen concentration of a sample solution
DE2912173C2 (en) Reactor / separator device
DE69832166T2 (en) MATRIX FOR SEPARATION AND USE OF MATRIX FOR SEPARATION
EP0154246B1 (en) Phase supports for the partition chromatography of macromolecules, process for their preparation and their use
DE2925565A1 (en) INCUBATIONAL DOUBLE SPACE IMMUNE DETECTION METHOD AND MEANS FOR IMPLEMENTING THE METHOD
CH615439A5 (en)
DE2839170A1 (en) CHROMATOGRAPHIC MATERIAL
DE10344820B4 (en) Adsorption membranes, processes for making the same and use of the adsorption membranes in devices
DD241748A5 (en) CLEANING BIOLOGICAL MATERIALS
DE3928201A1 (en) REMOVAL OF METALLIONS FROM WAESSEN SOLUTIONS
DE2322562A1 (en) METHOD FOR DETERMINING ONE OR MORE ANTIGENS IN A SAMPLE
DE2523207C2 (en) Procedure for determining the presence of antibodies
DE3720844C2 (en)
DE10344819A1 (en) Adsorption membrane for use e.g. in centrifuge tubes and micro-titration plates, comprises a microporous polymer membrane in which the pores contain porous, hydrocarbon-modified silicon dioxide particles
DE3130606A1 (en) Agent for forming antibodies
EP0035726B1 (en) Method and diagnostic agent for the immediate determination of the lipid content of beta-lipoproteins in blood
DE2912239C2 (en) Process for the production of a solid phase support for radioimmunoanalysis and its use in chromatographic columns
WO2002089975A1 (en) Adsorbents for the perfusion of blood and corresponding production method
CH636449A5 (en) Method for obtaining a new specific alpha-l-antikoerpers.
DE10013017A1 (en) Process for refining a viral antigen and producing a vaccine
DE10053553C2 (en) Device for the detection and enrichment of biomolecules
DE119279C (en)
DE3217032A1 (en) Simplified separation method for immunological determinations, dry chromatographic column for carrying out the method, and kit containing this
DE2165398A1 (en) Sintered elements for adsorption and distribution chromatographs and processes for their production

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee